An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of Dilaudid CR [hydromorphone controlled-release] in Patients With Chronic Low Back Pain.

Trial Profile

An Open-Label, Repeated-Dose Trial to Characterize the Efficacy and Safety, and Impact on Quality of Life Measures of Dilaudid CR [hydromorphone controlled-release] in Patients With Chronic Low Back Pain.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2009

At a glance

  • Drugs Hydromorphone (Primary)
  • Indications Back pain
  • Focus Therapeutic Use
  • Sponsors ALZA Corporation
  • Most Recent Events

    • 21 Jul 2009 Actual end date (Nov 2001) added as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2009 Actual patient number (207) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top